Additionally, there is a lack of data in certain subgroups (e.g., elderly patients, those with comorbidities like inflammatory bowel disease, or severe forms of PsA), highlighting the need for subgroup analyses to assess the efficacy and safety of IL-23 inhibitors in these populations. Here, IL23A is linked to inflammatory bowel disease.